Sigmoid Pharma is a privately held specialty pharmaceutical company developing targeted therapeutics for gastrointestinal diseases. The Company’s Single-Multiple Pill (SmPill®) technology is a versatile delivery system for solubilizing active therapeutic agents and allowing targeted release at the site of disease. The lead program is CyCol, a locally delivered cyclosporine for the treatment of ulcerative colitis (UC). CyCol releases cyclosporine directly into the colon, which minimizes systemic cyclosporine exposure and the resulting side effects. Sigmoid is planning to start a 140 patient Phase IIb study in the second quarter of 2016 to confirm CyCol dosing, and intends to initiate a Phase III trial in the first half of 2017 targeting patients with acute severe UC. A second Phase III trial is expected to launch in 2017 and will enroll patients with moderate to severe UC.